-
Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.
J Virol. 2003 Jan;77(1):353-65
PMID: 12477840
-
Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
J Virol. 2003 Feb;77(4):2310-20
PMID: 12551968
-
Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions.
J Virol. 2003 May;77(10):5678-84
PMID: 12719560
-
Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion.
J Virol. 2003 May;77(10):5829-36
PMID: 12719576
-
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.
J Virol. 2003 Oct;77(19):10557-65
PMID: 12970440
-
Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.
Virology. 2003 Sep 30;314(2):636-49
PMID: 14554091
-
Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes.
J Virol. 2003 Dec;77(23):12782-94
PMID: 14610200
-
Progress in the development of an HIV vaccine.
Expert Opin Emerg Drugs. 2003 May;8(1):37-45
PMID: 14610910
-
A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.
J Virol. 2004 Jan;78(1):146-57
PMID: 14671096
-
Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15812-7
PMID: 14668432
-
Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.
J Virol. 2004 Feb;78(3):1525-39
PMID: 14722307
-
Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.
Biochemistry. 2004 Feb 17;43(6):1410-7
PMID: 14769016
-
AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
Science. 2004 Jun 25;304(5679):1913-4
PMID: 15218131
-
Prospects for an AIDS vaccine: three big questions, no easy answers.
Lancet Infect Dis. 2004 Jul;4(7):397-413
PMID: 15219551
-
Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins.
AIDS Res Hum Retroviruses. 2004 Jul;20(7):772-87
PMID: 15307924
-
Polio vaccines and polioviruses.
Br Med J. 1977 Sep 17;2(6089):765
PMID: 912286
-
Synthesis and assembly of hepatitis B virus surface antigen particles in yeast.
Nature. 1982 Jul 22;298(5872):347-50
PMID: 7045698
-
Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.
Proc Natl Acad Sci U S A. 1990 Jan;87(2):648-52
PMID: 2300552
-
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.
J Virol. 1991 Feb;65(2):852-60
PMID: 1898972
-
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
J Virol. 2002 Jul;76(14):7306-21
PMID: 12072529
-
HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles.
Virology. 1991 Aug;183(2):487-95
PMID: 1906660
-
The ability of certain SIV vaccines to provoke reactions against normal cells.
Science. 1992 Jan 17;255(5042):292-3
PMID: 1549775
-
Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins.
J Virol. 1992 Jun;66(6):3306-15
PMID: 1583717
-
Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.
J Immunol. 2002 Jul 1;169(1):595-605
PMID: 12077293
-
Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus.
J Virol. 1992 Jun;66(6):3398-408
PMID: 1316455
-
Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response.
J Exp Med. 1992 Oct 1;176(4):1203-7
PMID: 1402662
-
Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines.
Science. 1992 Dec 18;258(5090):1935-8
PMID: 1470916
-
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
J Virol. 1994 Sep;68(9):6006-13
PMID: 8057475
-
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.
Science. 1994 Nov 11;266(5187):1024-7
PMID: 7973652
-
High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection.
AIDS Res Hum Retroviruses. 1994 Jul;10(7):839-51
PMID: 7986589
-
An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses.
Vaccine. 1995 Jan;13(1):54-60
PMID: 7762278
-
Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system.
Virology. 1995 Dec 1;214(1):50-8
PMID: 8525638
-
Virus-like particles as a rotavirus subunit vaccine.
J Infect Dis. 1996 Sep;174 Suppl 1:S88-92
PMID: 8752296
-
Maternal monoclonal antibody to the V3 loop alters specificity of the response to a human immunodeficiency virus vaccine.
J Infect Dis. 1996 Oct;174(4):866-9
PMID: 8843232
-
Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques.
Intervirology. 1996;39(1-2):93-103
PMID: 8957675
-
Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.
J Virol. 1997 Apr;71(4):2799-809
PMID: 9060635
-
Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells.
J Virol. 1997 Apr;71(4):3341-5
PMID: 9060707
-
Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
J Virol. 1997 Jun;71(6):4319-30
PMID: 9151820
-
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.
J Immunol. 1997 Jul 1;159(1):279-89
PMID: 9200464
-
Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions.
AIDS Res Hum Retroviruses. 1997 Nov 20;13(17):1497-500
PMID: 9390748
-
Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection.
Virology. 1998 May 25;245(1):65-74
PMID: 9614868
-
Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain.
J Virol. 1998 Sep;72(9):7620-5
PMID: 9696864
-
Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.
J Virol. 1998 Oct;72(10):7992-8001
PMID: 9733838
-
Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.
J Virol. 1998 Nov;72(11):9092-100
PMID: 9765454
-
Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.
J Virol. 1998 Nov;72(11):9384-91
PMID: 9765494
-
Fusion-competent vaccines: broad neutralization of primary isolates of HIV.
Science. 1999 Jan 15;283(5400):357-62
PMID: 9888845
-
Inhibition of the anti-V3 loop response to a recombinant gp120SF2 vaccine by preexisting monoclonal antibody.
AIDS Res Hum Retroviruses. 1999 Jun 10;15(9):855-60
PMID: 10381174
-
Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity.
Biologicals. 1998 Dec;26(4):255-65
PMID: 10403029
-
Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.
J Virol. 1999 Oct;73(10):8201-15
PMID: 10482571
-
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
J Virol. 2004 Dec;78(23):13232-52
PMID: 15542675
-
The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle.
J Virol. 2005 Jan;79(1):106-15
PMID: 15596806
-
Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41.
Virology. 2005 Mar 1;333(1):102-13
PMID: 15708596
-
Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months.
Vaccine. 2005 Apr 8;23(20):2602-6
PMID: 15780442
-
Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.
J Virol. 2005 Apr;79(8):4927-35
PMID: 15795278
-
Antigenic conservation and immunogenicity of the HIV coreceptor binding site.
J Exp Med. 2005 May 2;201(9):1407-19
PMID: 15867093
-
Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
J Virol. 2005 Jun;79(11):7059-67
PMID: 15890945
-
Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239.
J Virol. 2005 Jun;79(12):7707-20
PMID: 15919923
-
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
J Virol. 2005 Jul;79(14):8812-27
PMID: 15994775
-
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.
J Virol. 2005 Aug;79(16):10108-25
PMID: 16051804
-
Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.
J Virol. 2005 Aug;79(16):10210-7
PMID: 16051814
-
Comparing antigenicity and immunogenicity of engineered gp120.
J Virol. 2005 Oct;79(19):12148-63
PMID: 16160142
-
Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.
J Virol. 2005 Dec;79(23):14804-14
PMID: 16282480
-
Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
J Virol. 2006 Feb;80(3):1414-26
PMID: 16415019
-
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.
J Virol. 2006 Mar;80(5):2515-28
PMID: 16474158
-
Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.
Hum Antibodies. 2005;14(3-4):101-13
PMID: 16720980
-
Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.
J Virol. 2006 Jun;80(12):6155-64
PMID: 16731954
-
Distribution and three-dimensional structure of AIDS virus envelope spikes.
Nature. 2006 Jun 15;441(7095):847-52
PMID: 16728975
-
Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
J Virol. 2006 Sep;80(17):8745-62
PMID: 16912322
-
Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ.
PLoS Pathog. 2006 Aug;2(8):e83
PMID: 16933990
-
Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies.
J Virol. 2006 Dec;80(24):11991-7
PMID: 17005652
-
Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
Virology. 2007 Feb 20;358(2):334-46
PMID: 17011011
-
Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.
Virology. 2007 Mar 30;360(1):199-208
PMID: 17092531
-
A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
Virology. 2007 Apr 10;360(2):329-40
PMID: 17126869
-
Immunogenicity of full length and truncated SIV envelope proteins.
Viral Immunol. 1999;12(3):205-15
PMID: 10532649
-
A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms.
J Immunol. 1999 Dec 15;163(12):6756-61
PMID: 10586074
-
Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
Virology. 2000 Jan 5;266(1):66-78
PMID: 10612661
-
A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
J Virol. 2000 Jan;74(2):627-43
PMID: 10623724
-
Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.
J Virol. 2000 Feb;74(4):1961-72
PMID: 10644369
-
Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?
Nat Med. 2000 Feb;6(2):123-5
PMID: 10655088
-
Production and characterization of simian--human immunodeficiency virus-like particles.
AIDS Res Hum Retroviruses. 2000 Feb 10;16(3):227-36
PMID: 10710211
-
Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.
J Virol. 2000 May;74(10):4746-54
PMID: 10775613
-
Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1.
J Virol. 2000 Jul;74(13):5802-9
PMID: 10846059
-
Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.
J Virol. 2000 Sep;74(17):7922-35
PMID: 10933700
-
[Macaque immunization with virions purified from a primary isolate of the human immunodeficiency virus type 1 induced enhancement antibodies].
Bull Acad Natl Med. 2000;184(1):67-84; discussion 85-7
PMID: 10989532
-
Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate.
J Biol Chem. 2000 Nov 10;275(45):35137-45
PMID: 10926931
-
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
J Virol. 2001 Jan;75(2):645-53
PMID: 11134278
-
Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.
J Virol. 2001 Mar;75(5):2041-50
PMID: 11160708
-
AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies.
J Virol. 2001 May;75(9):4424-9
PMID: 11287594
-
A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.
J Infect Dis. 2001 May 15;183(10):1485-93
PMID: 11319684
-
Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.
J Virol. 2001 Jul;75(13):5879-90
PMID: 11390589
-
Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer.
J Biol Chem. 2001 Oct 26;276(43):39577-85
PMID: 11514580
-
Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.
J Virol. 2002 Jan;76(2):730-42
PMID: 11752163
-
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.
J Virol. 2002 Mar;76(6):2606-16
PMID: 11861826
-
Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.
J Virol. 2002 Mar;76(6):2683-91
PMID: 11861835
-
Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.
J Virol. 2002 Mar;76(6):2835-47
PMID: 11861851
-
Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins.
J Virol. 2002 Apr;76(7):3511-21
PMID: 11884575
-
Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.
J Virol. 2002 Jun;76(11):5315-25
PMID: 11991960
-
Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.
J Virol. 2002 Jun;76(11):5357-68
PMID: 11991964
-
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8
PMID: 11997472
-
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.
J Virol. 2002 Jul;76(14):7293-305
PMID: 12072528
-
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.
J Virol. 2002 Aug;76(15):7760-76
PMID: 12097589
-
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
J Virol. 2002 Sep;76(17):8875-89
PMID: 12163607
-
A controlled trial of a human papillomavirus type 16 vaccine.
N Engl J Med. 2002 Nov 21;347(21):1645-51
PMID: 12444178